Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Measuring insulin production after a meal shake in type 2 diabetes

Tests how well people with type 2 diabetes make insulin after a meal shake.

Plain-language title generated from the registry record
Registry title: Pancreatic Insulin Production Capacity (PIPC) - a Feasibility Study

Key facts

Where
Ottawa, CanadaSee the site

Where in Canada

  • The Ottawa HospitalOttawa, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ottawa Hospital Research Institute
Trial code
NCT06462170
Record updated
6 May 2026
Original description
The standard treatment for Type 2 diabetes involves management of the disease based on average of blood glucose control over the past few months.Read full original descriptionShow less

The Feasibility of an Innovative Protocol to Demonstrate the Impact of Positive Energy Balance on Pancreatic Insulin Production Capacity (PIPC)

The standard treatment for Type 2 diabetes involves management of the disease based on average of blood glucose control over the past few months.

In this study, the investigators test for the participants' ability to produce insulin, which is the hormone that the body makes to control blood sugar levels. The body produces insulin in response to eating. The participants will drink a meal replacement shake, and then test the blood for levels of insulin produced over 2 hours.

With blood tests taken five times over two hours, the investigators will measure the blood glucose (sugar), and insulin levels. This study will assess the differences in insulin produced in the participants and try to understand the reasons for these differences.

Inclusion: Consent provided; Age >= 18 years; Diagnosed as type 2 diabetes mellitus; Not on insulin therapy.

Exclusion: Diagnosed as another form of diabetes mellitus; Allergic to one or more ingredients in Boost meal replacement shake; Unable to fast since midnight and attend in person for the morning protocol.

ClinicalTrials.gov NCT06462170